Literature DB >> 32412772

Clinical significance of perioperative EMT-CTC in rectal cancer patients receiving open/laparoscopic surgery.

W Yin1, Y M Han2,3, Z L Li2, Z X Huang2, L Huang2, X G Zhong2.   

Abstract

The objective of this study was to explore the clinical significance of perioperative CTCs (circulating tumor cells) counts and EMT-CTCs (epithelial-mesenchymal transition-CTCs) in rectal cancer patients. A total of 30 patients with rectal cancer who underwent radical resection of rectal cancer at the Guangxi Zhuang Autonomous Region People's hospital were enrolled. Five ml peripheral blood was withdrawn from 30 patients with rectal cancer before the operation and seven days after the operation and at the corresponding time also from 20 healthy volunteers. CanPatrol™ CTC detection technique was used to enrich and identify CTCs and IER3 expression simultaneously. We found out that the preoperative total CTCs were correlated with lymph node metastasis (p=0.008) and tumor size, and mixed CTCs were closely correlated with lymph node metastasis (p=0.009). The number of IER3-positive total CTCs and mesenchymal CTCs were statistically associated with tumor size, p=0.034 and 0.043, respectively. The number of CTCs varied significantly before and after the operation in all patients (p=0.049). There were significant differences in CTCs variations between the open operation group and the laparoscopic operation group. In the laparoscopic operation group, the average number of single-cell CTCs was 6.9 before operation and 3.5 after the operation (p=0.013). In the open operation group, the average number of single-cell CTCs was 5.9 before operation and 4.2 after the operation. To conclude, surgery is associated with a decrease of CTCs in rectal cancer patients, especially in patients receiving laparoscopic surgery. The number of CTCs before the operation in rectal cancer patients is related to the size of tumors and regional lymph node metastasis. CTCs detection and characterization may be useful for clinical staging and lymph node dissection during operation.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32412772     DOI: 10.4149/neo_2020_190709N611

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  5 in total

1.  Circulating tumor cells with epithelial-mesenchymal transition markers as potential biomarkers for the diagnosis of lung cancer.

Authors:  Sha-Sha Jiang; Chun-Guo Mao; Yong-Geng Feng; Bin Jiang; Shao-Lin Tao; Qun-You Tan; Bo Deng
Journal:  World J Clin Cases       Date:  2021-04-26       Impact factor: 1.337

2.  Role of Phenotypes of Circulating Tumor Cells in the Diagnosis and Treatment of Colorectal Cancer.

Authors:  Yuchen Zhong; Tianyi Ma; Tianyu Qiao; Hanqing Hu; Zhengliang Li; Kangjia Luo; Yuliuming Wang; Qingchao Tang; Guiyu Wang; Rui Huang; Xishan Wang
Journal:  Cancer Manag Res       Date:  2021-09-10       Impact factor: 3.989

3.  Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma.

Authors:  Qing Yan; Hao-Ming Lin; Ke Zhu; Yi Cao; Xiao-Lin Xu; Zi-Yu Zhou; Lei-Bo Xu; Chao Liu; Rui Zhang
Journal:  Front Oncol       Date:  2022-02-22       Impact factor: 6.244

4.  Application of Circulating Tumor Cells and Circulating Free DNA from Peripheral Blood in the Prognosis of Advanced Gastric Cancer.

Authors:  Pengjie Yu; Shengmao Zhu; Yushuang Luo; Ganggang Li; Yongqiang Pu; Baojia Cai; Chengwu Zhang
Journal:  J Oncol       Date:  2022-01-11       Impact factor: 4.375

5.  BCAR1 plays critical roles in the formation and immunoevasion of invasive circulating tumor cells in lung adenocarcinoma.

Authors:  Chun-Guo Mao; Sha-Sha Jiang; Xiao-Yang Wang; Shao-Lin Tao; Bin Jiang; Cheng-Yi Mao; Yan-Lian Yang; Zhi-Yuan Hu; Tan Long; Hua Jin; Qun-You Tan; Yi Huang; Bo Deng
Journal:  Int J Biol Sci       Date:  2021-06-11       Impact factor: 6.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.